[Form 4] Neurocrine Biosciences Inc Insider Trading Activity

Rhea-AI Filing Summary

Stephen A. Sherwin, a director of Neurocrine Biosciences Inc. (NBIX), reported a non-market transfer of 1,000 shares of the company's common stock on 09/02/2025 coded as a gift (transaction code G(1)). The form shows $0 as the price because no cash was received for the gifted shares. After the transaction, Mr. Sherwin beneficially owned 12,542 shares, held directly. The filing was executed by attorney-in-fact Darin Lippoldt and dated 09/03/2025. The Form 4 discloses this change in beneficial ownership and follows Section 16 reporting requirements.

Positive

• Timely disclosure of the transaction with required fields completed
• Clear explanation that the 1,000-share transfer was a gift with $0 reported price

Negative

• Reduction in director's direct holdings by 1,000 shares to a post-transaction total of 12,542 shares
• No additional context provided about recipient or purpose beyond 'gift/charitable contribution'

Insights

Securities Compliance Analyst

TL;DR Insiders reported a gift of 1,000 shares, reducing direct holdings to 12,542; filing appears procedural and compliant.

The Form 4 documents a non-market transfer by a director using transaction code G(1), indicating a gift or charitable contribution with no cash exchange. The report includes the transaction date, resulting beneficial ownership, and a signature executed by an attorney-in-fact. For compliance reviewers, the filing contains the required fields: reporting person, issuer ticker, transaction details, ownership form, and explanatory remark. There is no price because the transfer was a gift. The disclosure meets Section 16(a) presentation standards based on the provided text.

Corporate Governance Specialist

TL;DR Director made a charitable gift of 1,000 shares; disclosure is clear and routine under insider reporting rules.

From a governance perspective, the filing transparently records a decrease in direct beneficial ownership from the reported post-transaction total. The use of an attorney-in-fact signature is properly noted. The Form 4 includes an explanation clarifying the transfer was a gift effective on the reported date, which helps stakeholders understand the nature of the transaction without suggesting a market disposition. No additional contextual details are provided in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERWIN STEPHEN A

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		G(1)		1,000	D	$0	12,542	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a gift/charitable contribution effective September 2, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NBIX director Stephen A. Sherwin report on Form 4?

The Form 4 reports a gift of 1,000 shares of Neurocrine Biosciences (NBIX) common stock on 09/02/2025, with no cash received.

How many NBIX shares does Stephen A. Sherwin own after the reported transaction?

Following the transaction, the filing shows Mr. Sherwin beneficially owned 12,542 shares, held directly.

Why is the price listed as $0 on the NBIX Form 4?

The price is $0 because the transaction was a gift/charitable contribution and was not a market sale or purchase.

When was the Form 4 for the NBIX transaction signed and by whom?

The filing was executed by Darin Lippoldt, Attorney-in-Fact and dated 09/03/2025.

What does transaction code G(1) mean on this Form 4?

On this filing, transaction code G(1) is used to indicate the reported transfer was a gift or charitable contribution, as stated in the explanation.